<DOC>
	<DOCNO>NCT02509208</DOCNO>
	<brief_summary>The purpose European study demonstrate safety performance SurgiClot® dress treatment cancellous bone bleeding .</brief_summary>
	<brief_title>A Study Assess Safety Performance SurgiClot® Treatment Cancellous Bone Bleeding</brief_title>
	<detailed_description>Patients require surgery iliac crest bone graft ( ICBG ) , pelvic osteotomy spinal fusion screen multicenter , prospective , non-randomized , open-label study . All qualified subject treat SurgiClot® haemostatic dressing ( completely soluble dress consist solid nanofibers electrospun dextran embed lyophilized human fibrinogen thrombin protein ) . The safety performance SurgiClot dressing evaluate 40 subject enrol Europe . Subjects follow six week surgery .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Hemostatics</mesh_term>
	<criteria>Patients undergo planned elective orthopaedic spinal surgical procedure . Spinal surgery entire spine although confined one twolevel fusion e.g . one two level cervical , thoracic lumbar . Patient intraoperative bleeding site involve cancellous bone surgeon would typically treat another topical haemostatic agent control bleed . Patient normal liver function The subject willing able comply requirement study protocol , include six week followup evaluation . Is unable unwilling return followup visit . The subject surgery intend application site ≤ 6 month current surgical procedure . Active infection surgical site . Pregnancy , determine urine pregnancy test , breast feeding . Preoperative platelet count &lt; 150,000 , INR &gt; 1.3 , and/or APTT &gt; 32.4 . Preoperative anaemia ( Hb &lt; 110 g/L female , Hb &lt; 120 g/L male ) . Use anticoagulant therapy ( e.g. , coumadin , heparin , clopidogrel ) , nonsteroidal antiinflammatory medication fish oil supplement within 7 day surgery except aspirin . ( maximum dose 150 mg per day ) Patient blood dyscrasia . Presence spinal tumour , intradural pathology , prior spinal fusion surgery target site . Participation another clinical trial investigational drug device within past 30 day . Known allergy human fibrinogen , human thrombin , porcinederived product . Compromised immune system . The use haemostatic agent contraindicate subject . Fibrinolytic disorder require intraoperative antifibrinolytic treatment . Haematological disease ( thromboembolic event , haemoglobinopathy , coagulopathy haemolytic disease ) Significant comorbidities : Previous myocardial infarction ( MI ) ; severe ischemic heart disease ( New York Heart Association Class III , IV ) ; severe pulmonary disease ; chronic renal failure ; hepatic failure ; uncontrolled hypertension . Subject unwilling receive blood product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>iliac crest bone graft</keyword>
	<keyword>ICBG</keyword>
	<keyword>pelvic osteotomy</keyword>
	<keyword>spinal fusion</keyword>
	<keyword>hemostasis</keyword>
	<keyword>haemostasis</keyword>
	<keyword>hemostatic</keyword>
	<keyword>haemostatic</keyword>
	<keyword>dextran</keyword>
	<keyword>SurgiClot</keyword>
	<keyword>cancellous bone bleeding</keyword>
</DOC>